Molecular Partners (MLLCF) to Release Quarterly Earnings on Thursday

Molecular Partners (OTCMKTS:MLLCF) is expected to issue its results before the market opens on Thursday, March 12th. Analysts expect the company to announce earnings of ($0.3910) per share for the quarter.

Molecular Partners Stock Performance

Molecular Partners stock opened at $2.25 on Wednesday. Molecular Partners has a 12 month low of $2.25 and a 12 month high of $4.15. The stock’s 50-day moving average is $2.70 and its 200-day moving average is $3.34.

About Molecular Partners

Molecular Partners AG is a clinical-stage biotechnology company headquartered in Zurich, Switzerland, specializing in the development of novel protein therapeutics based on its proprietary DARPin® (Designed Ankyrin Repeat Proteins) platform. The company’s pipeline focuses on precision molecules engineered for oncology and immuno-inflammatory diseases, as well as antiviral and anti-infective applications. By leveraging the modular nature of DARPin® science, Molecular Partners designs small, highly stable binding proteins that can engage multiple targets simultaneously, potentially improving efficacy and safety profiles over conventional antibody approaches.

Founded in 2004 by Professor Andreas Plückthun at the University of Zurich, Molecular Partners has advanced several clinical-stage candidates through Phase 1 and Phase 2 trials.